Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis
- 24 November 2010
- journal article
- Published by Springer Nature in Apoptosis
- Vol. 16 (3) , 311-320
Abstract
Resistance to cisplatin chemotherapy remains a major hurdle preventing effective treatment of many solid cancers. BAX and BAK are pivotal regulators of the mitochondrial apoptosis pathway, however little is known regarding their regulation in cisplatin resistant cells. Cisplatin induces DNA damage in both sensitive and resistant cells, however the latter exhibits a failure to initiate N-terminal exposure of mitochondrial BAK or mitochondrial SMAC release. Both phenotypes are highly sensitive to mitochondrial permeabilisation induced by exogenous BH3 domain peptides derived from BID, BIM, NOXA (which targets MCL-1 and A1), and there is no significant change in their prosurvival BCL2 protein expression profiles. Obatoclax, a small molecule inhibitor of pro-survival BCL-2 family proteins including MCL-1, decreases cell viability irrespective of platinum resistance status across a panel of cell lines selected for oxaliplatin resistance. In summary, selection for platinum resistance is associated with a block of mitochondrial death signalling upstream of BAX/BAK activation. Conservation of sensitivity to BH3 domain induced apoptosis can be exploited by agents such as obatoclax, which directly target the mitochondria and BCL-2 family.Keywords
This publication has 34 references indexed in Scilit:
- Induction of autophagy-dependent necroptosis is required for childhood acute lymphoblastic leukemia cells to overcome glucocorticoid resistanceJournal of Clinical Investigation, 2010
- A Bax-Mediated Mechanism for Obatoclax-Induced Apoptosis of Cholangiocarcinoma CellsCancer Research, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- AT-101 induces apoptosis in CLL B cells and overcomes stromal cell–mediated Mcl-1 induction and drug resistanceBlood, 2009
- Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosisProceedings of the National Academy of Sciences, 2007
- Proapoptotic BID Is an ATM Effector in the DNA-Damage ResponseCell, 2005
- DNA damage response as a candidate anti-cancer barrier in early human tumorigenesisNature, 2005
- BCL-2 Selectively Interacts with the BID-induced Open Conformer of BAK, Inhibiting BAK Auto-oligomerizationJournal of Biological Chemistry, 2003
- A Role for Mitochondrial Bak in Apoptotic Response to Anticancer DrugsJournal of Biological Chemistry, 2001
- Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and DeathScience, 2001